Robert J. Moots

Robert J. Moots

Edge Hill University
Ormskirk, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 153 publications

Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review.

Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review.

Journal: Expert review of clinical immunology

Published: September 03, 2026

Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.

Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.

Journal: EULAR rheumatology open

Published: August 01, 2026

Management of mucocutaneous and joint involvement of Behçet's syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.

Management of mucocutaneous and joint involvement of Behçet's syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.

Journal: EULAR rheumatology open

Published: August 01, 2026

EULAR recommendations for the management of Behçet's syndrome: 2025 update.

EULAR recommendations for the management of Behçet's syndrome: 2025 update.

Journal: Annals of the rheumatic diseases

Published: December 15, 2025

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2025.

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2025.

Journal: Rheumatology (Oxford, England)

Published: September 29, 2025

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2025.

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2025.

Journal: The British journal of dermatology

Published: September 26, 2025

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.

Journal: Rheumatology and therapy

Published: September 06, 2025

Developing Rheumatology in Sub-Saharan Africa: Addressing the Challenges.

Developing Rheumatology in Sub-Saharan Africa: Addressing the Challenges.

Journal: The Journal of rheumatology

Published: August 01, 2025

Enhance the transparency in the development of the British Association of Dermatologists' living guidelines: reply from authors.

Enhance the transparency in the development of the British Association of Dermatologists' living guidelines: reply from authors.

Journal: The British journal of dermatology

Published: April 17, 2025

Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trial.

Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trial.

Journal: Rheumatology and immunology research

Published: February 13, 2025

Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives.

Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives.

Journal: Biomedicines

Published: December 18, 2024

Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review.

Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review.

Journal: Autoimmunity reviews

Published: November 13, 2024

Showing 1-12 of 153

Last Updated: 09/26/2026